Flow cytometry analysis revealed that COH29 treatment caused cell cycle arrest in the G1 phase in ESCC cells. In vivo studies further validated COH29's robust growth suppression of ESCC, highlighting its potential as a therapeutic agent.

6 months ago

Journal

PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) • GCG (Glucagon)

COH29

10ms

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists (clinicaltrials.gov)

P1, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jun 2025

10 months ago

Trial completion date

COH29

1year

RRM2 inhibition alters cell cycle through ATM/Rb/E2F1 pathway in atypical teratoid rhabdoid tumor. (PubMed, Neoplasia)

Our study highlights the role of ATM/Rb/E2F1 pathway in controlling cell cycle arrest and apoptosis in response to RRM2 inhibition-induced DNA damage. This provides insight into the therapeutic benefits of COH29 and suggests targeting this pathway as a potential treatment for ATRT.

1 year ago

Journal

HRD (Homologous Recombination Deficiency) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • E2F1 (E2F transcription factor 1)

COH29

almost2years

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists (clinicaltrials.gov)

P1, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

almost 2 years ago

Trial completion date

COH29

almost2years

Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. (PubMed, J Exp Clin Cancer Res)

Collectively, our study uncovers the oncogenic functions of RRM2 in ATRT cell lines, and highlights the therapeutic potential of targeting RRM2 in ATRT. The promising effect of COH29 on ATRT suggests its potential suitability for clinical trials as a novel therapeutic approach for ATRT.

almost 2 years ago

Journal

RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

COH29

2years

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment. (PubMed, Cell Biosci)

Our findings suggest that RRM2 regulates docetaxel resistance in prostate cancer by stabilizing ANXA1-mediated activation of the PI3K/AKT pathway. Targeting RRM2 or ANXA1 may offer a promising therapeutic strategy to overcome docetaxel resistance in prostate cancer.

2 years ago

Journal

ANXA1 (Annexin A1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

AKT1 overexpression • ANXA1 overexpression • ANXA1 expression

docetaxel • COH29

over2years

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists (clinicaltrials.gov)

P1, N=12, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting | N=19 --> 12 | Trial completion date: Dec 2022 --> Dec 2023

over 2 years ago

Enrollment closed • Enrollment change • Trial completion date

H2AX (H2A.X Variant Histone)

COH29